The significance of polymorphisms in genes encoding Il-1β, Il-6, TNFα, and Il-1RN in the pathogenesis of intraventricular hemorrhage in preterm infants

Dawid Szpecht¹ · Janusz Gadzinowski¹ · Agnieszka Seremak-Mrozikiewicz²,³ · Grażyna Kurzawińska⁵ · Krzysztof Drews⁵ · Marta Szymankiewicz¹

Received: 2 March 2017 / Accepted: 14 May 2017 / Published online: 29 June 2017
© The Author(s) 2017. This article is an open access publication

Abstract

Introduction Intraventricular hemorrhage (IVH) is a significant morbidity seen in very low birth weight infants. Genes related to inflammation may be risk factors for IVH.

Material and methods We examined five polymorphisms for an association with IVH in 100 preterm infants born from singleton pregnancy, before 32 + 0 weeks of gestation, exposed to antenatal steroid therapy, and without congenital abnormalities. These polymorphisms include interleukin-1β 3953C>T, interleukin-6 −174G>C and −596G>A, tumor necrosis factor −308G>A, and 86 bp variable number tandem repeat polymorphism of interleukin-1 receptor antagonist (Il-1RN 86 bp VNTR).

Results In our study population, 45 (45%) infants developed IVH, including 15 (33.33%) with stage 1, 19 (42.22%) with stage 2, 8 (17.77%) with stage 3, and 3 (6.66%) with stage 4. In contrast to the previously published data, the prevalence of IVH did not vary between infants with different IL-6 and TNFα alleles and genotypes. Our novel investigations in Il-1 + 3953C>T and Il-1RN 86 bp VNTR polymorphism did not show any significant link between those alleles or genotypes and IVH.

Conclusions IVH is a significant problem for preterm infants. In addition to little progress in preventing IVH in preterm babies, substantial research that are focused on understanding the etiology, mechanism and risk factors for IVH are imperative. In the era of personalized medicine, identification of genetic risk factors creates opportunities to generate preventative strategies. Further studies should be performed to confirm the role of genetic factors in etiology and pathogenesis of IVH.

Keywords Intraventricular hemorrhage · Gene polymorphism · Preterm neonates

Introduction

Intraventricular hemorrhage (IVH) is a condition which mainly affects infants born before 32 weeks of pregnancy. Approximately 90% of IVH cases occur within the first 3 days of the newborn’s life, and in 20–40% of cases, the spread of the initial bleeding becomes more extensive. IVH ranges in severity from grade 1 to the most severe grade 4. So far, the following risk factors for IVH have been described in literature: birth before 32 weeks of gestation, birth weight less than 1500 g, absence of prophylactic prenatal steroid therapy in women at risk of premature delivery, early clamping of the umbilical cord (up to 30 s after birth), symptoms of intrauterine infection in the mother and the newborn, and labor and delivery complicated by bleeding, perinatal hypoxia, respiratory distress syndrome (RDS), or patent ductus arteriosus (PDA) [1–3].

Contemporarily, it is thought that genetic factors may play a significant role in the development of IVH, but their connection with IVH in newborns has yet to be proven by lany clinical studies. Undoubtedly, factors involved in the inflammatory processes such as interleukin-1β (II-1β), interleukin 6 (II-6), tumor necrosis factor alpha (TNFα), and
interleukin-1 receptor antagonist (II-1RN) play a role in the pathogenesis of IVH. IVH is multifactorial and complex complication of prematurity and primarily is attributed to the intrinsic fragility of the germinal matrix vasculature and the disturbance in the cerebral blood flow. Inflammation may directly or indirectly increase either the fluctuation in cerebral blood flow or the fragility of the germinal matrix microvasculature [3]. Neonatal infections are an important cause of morbidity and mortality and are associated with an increased risk of long-term neurological complications [4]. Genetic determination of the individual inflammatory response may influence the susceptibility to poor outcome after systemic infection or severe tissue damage [5]. Better understanding of the genetic factors that contribute to IVH and constitute a major role in its pathogenesis would be of great benefit in perinatal care to prevent brain injury and abnormal development.

The aim of this study was to evaluate the possible relationship between five polymorphisms in genes encoding II-1β, II-6, TNFα, and II-1RN and the occurrence of IVH in a population of preterm newborns.

**Objectives**

Between June 1, 2014, and August 15, 2016, 428 premature infants were born from 24+0 to 32+0 weeks of gestation and admitted to the neonatal intensive care unit at the Poznan University of Medical Sciences. Considering exclusion criteria, 100 (23.4%) out of the 432 infants were included in the study. In order to guarantee a homogenous ethnic background, all subjects were of Caucasian origin. The study did not include neonates born before 24+0 and after 32+0 weeks of pregnancy; multiple pregnancy neonates; pregnancies complicated by death of one of the fetuses; chromosomal abnormalities; toxoplasmosis, other, rubella, cytomegalovirus, herpes (TORCH) infections; inborn errors of metabolism; or infants without antenatal steroid therapy (AST).

**Materials and methods**

**Clinical features**

Studied perinatal factors that may interfere with the development of IVH include gender, gestational age (GA; weeks), birth weight (BW, grams), and small for gestational age (SGA, birth weight under the 3rd percentile). The type of delivery (vaginal birth vs. cesarean section), birth asphyxia (defined as Apgar score less than 6 at 10 min and pH <7.0 or blood base excess (BE) <=−12 mmol/l in cord blood), and intrauterine infection (defined as positive culture in sterile blood originally accompanied by clinical symptoms or pneumonia developed in 48 h after the birth) could deter IVH development.

**Diagnosis**

IVH was diagnosed with the use of a cranial ultrasound (10 MHz transducer, ProSound α7 Premier, Aloka). Routine cranial ultrasound examinations were performed on the 1st, 3rd, and 7th days after birth, in accordance with local standards and recommendations in infants born below 32 weeks gestation. Parents have consented to the cranial ultrasound. The maximal degree of IVH was confirmed by cranial ultrasound on the 7th day of life. The classification of intraventricular bleeding was based on the Papille IVH classification [6].

**Studied polymorphisms**

We studied five single-nucleotide polymorphisms: II-1β +3953C>T, II-6 −174G>C and −596G>A, TNFα −308G>A, and 86 bp variable number tandem repeat polymorphism of interleukin-1 receptor antagonist (II-1RN VNTR 86 bp).

A blood sample (0.5 ml) was taken directly post delivery and banked. Genomic DNA was extracted from blood leukocytes using QIAamp DNA Blood Mini Kit (Qiagen Inc, Germany). Genotyping was performed using polymerase chain reaction (PCR) procedures. The description of those studied polymorphisms in II-1, II-6, II-1RN VNTR, and TNFα genes is shown in Table 1.

Informed parental consent was obtained from each participating infant. The study followed the tenets of the Declaration of Helsinki and was approved by the Bioethics Committee of Poznan University of Medical Sciences (66/14 and 799/16). Furthermore, all methods and examinations were performed in accordance with the relevant ethical guidelines and regulations.

**Statistical analysis**

The results are presented as percentage for categorical variables, or median (range) for non-normally distributed continuous variables as tested by the Shapiro–Wilk test. A p value of less than 0.05 was considered significant. The Fisher exact probability test, the chi-squared test, the Fisher–Freeman–Halton test, and the chi-squared test with Yates correction were used to evaluate the association between IVH and categorical variables. Differences in non-normally distributed continuous variables were compared by the Mann–Whitney U test. The expected genotype frequencies were calculated from allele frequencies with the Hardy–Weinberg equilibrium. Statistical analysis was performed using CytelStudio version 10.0, created on January 16, 2013 (CytelStudio Software Corporation, Cambridge, MA, USA), and Statistica version 10, 2011 (StatSoft, Inc., Tulsa, OK, USA).
Table 1 Description of the five studied polymorphisms in Il-1, Il-6, Il-1RN, and TNFα genes

| Gene symbol | Polymorphism | Sequence of primers | Restriction enzyme | Products |
|-------------|--------------|---------------------|--------------------|----------|
| IL-1β (rs1143634) | +3953C>T | F 5′-gTTgTC ATC Aga CTT TgA CC-3′ R 5′-TTC AgT TCA TAT ggA CCA gA-3′ | TaqI (Thermo Scientific) | CC 137,114 bp, CT 251,137,114 bp TT 251 bp |
| IL-1RN (rs2234663) | 86 bp VNTR | F 5′-CTC AgC AAC ACT CCT AT-3′ R 5′-TCC Tgg TCT gCAggT AA-3′ | IL1RN*0 154 bp IL1RN*1 410 bp IL1RN*2 240 bp IL1RN*3 500 bp IL1RN*4 325 bp IL1RN*5 595 bp |
| IL-6 (rs1800795) | −174G>C | F 5′-ACA TgC CAA gTgCTgAgT CA-3′ R 5′-AAT CTT TgTggAggTg Ag-3′ | Lwel (Thermo Scientific) | GG 114,100 bp GC 214,114,100 bp CC 214 bp |
| IL-6 (rs1800797) | −596G>A | F 5′-ggAgTgC ACA CAC TCC ACC Tg-3′ R 5′-AagCAg CAC ACC TCC ACT TTT ACT T-3′ | BseGI (BstClI) (Thermo Scientific) | GG 420 bp GA 420,354,66 bp AA 354, 66 bp |
| TNF-α (rs1800629) | −308G>A | 5′-AAA TggAgg CAA Tag gTTTgAggCTTg-3′ 5′-TAC CCC TCA CAC TCC CCA TCC TCCCTg ATC-3′ | FaqI (BsmFI) (Thermo Scientific) | GG 86,45 bp GA 131,86,45 bp AA 131 bp |

Results

We found that 45 (45%) infants developed IVH in our study population, including 15 (33.33%) with grade 1, 20 (42.22%) with grade 2, 8 (17.77%) with grade 3, and 3 (6.66%) with grade 4. The prevalence of IVH was comparable in female infants who developed IVH: 1.761). Similarly, in infants born from 24 + 0 to 28 + 6 weeks of gestation, the following genotypes had greater prevalence: GC (OR 1.379; 0.45–4.416) and CC (OR 1.625; 0.379–7.013) II-6 −174G>C; GA (OR 1.754; 0.587–5.504) and AA (OR 1.667; 0.384–7.223) II-6 −596G>A; and CT IL-1β +3953C>T (OR 0.674; 0.253–1.761). Similarly, in infants born from 24 + 0 to 28 + 6 weeks of gestation, the following genotypes had greater prevalence: GC (OR 2.6; 0.529–12.93) and CC (OR 4.8; 0.294–275) II-6 −174G>C; GA (OR 2.7; 0.551–13.39) and AA (OR 3.6; 0.191–219.9) II-6 −596G>A; and CT IL-1β +3953C>T (OR0.4; 0.999–1.625). These findings, however, were not statistically significant. Analysis showed higher prevalence of grade 3 and 4 IVH in children born from 24 + 0 to 32 + 0 weeks of gestation with the following genotypes: GC (OR 1.644; 0.298–16.9) II-6 +3953C>T; GA (OR 1.853; 0.338–18.93) II-6 −596G>A; and 2/2 II-1RN (OR 1.917; 0.154–15.15). This same correlation was not present in children born from 24 + 0 to 28 + 6 weeks of gestation. Our investigation also revealed that infants with genotype 1/2 II-1RN may have higher prevalence of grade 3 and 4 IVH (born from 24 + 0 to 32 + 0 weeks of gestation (OR 2.054; 0.401–11.17) and born from 24 + 0 to 28 + 6 weeks of gestation (OR 3.636; 0.568–26.85)). These results were not statistically significant. Genotype distribution of the polymorphisms in infants without and with IVH or without/with IVH grades 1–2 and with IVH grades 3–4 is presented in Table 3 as well as in infants born between 24 + 0 and 28 + 6 weeks of gestation without and with IVH or without/with IVH grades 1–2 and with IVH grades 3–4 are presented in Table 4. The analysis did not show any higher prevalence of studied genotypes in infected and non-infected patients with IVH (Table 5).

Discussion

In our study, we evaluated the possible association between II-1, II-6, TNFα, and II-1RN VNTR gene polymorphisms and the development of IVH, in a large study population of preterm infants born from 24 + 0 to 32 + 0 weeks of gestation with the exposition on AST. AST is administered to women in the case of suspicion of preterm delivery and has been proven to reduce the prevalence and severity of IVH [7–9]. IVH has been attributed to alteration in cerebral blood flow to the germinal matrix, which, as suggested by risk factor studies, might be responsible
for the genes contributing to the infection and inflammation response. Inflammatory factors including cytokines such as IL-1, IL-6, and TNFα have been implicated in IVH development [10]. In the population of Polish women, maternal carriage of polymorphic alleles of IL-1β, IL-6 promoter, TNF-α promoter, and IL-1RN seems to have no impact on the risk of preterm delivery due to preterm premature rupture of membranes [11].

Il-1 is produced by activated macrophages and stimulates the production of other pro-inflammatory cytokines, such as interferon-γ, IL-6, and TNFα. Subtype Il-1β is mostly responsible for the pro-inflammatory effects and for hypothalamic–pituitary–adrenal axis activation. II-1β is developmentally and regionally regulated in the brain of developing fetuses and neonates [12, 13]. Increased levels of II-1β were observed in amniotic fluid and/or cord blood of infants with perinatal brain injury including IVH and periventricular leukomalacia (PVL) [14]. A previous study by Ryckman et al. demonstrated that infants born before 32 weeks of gestation with the CT genotype or the II-1β −31 C allele were at higher risk for IVH grades 1 and 2 and those with the CC genotype or C allele were at higher risk for IVH grades 3 and 4 [15]. The II-1β −3I allele C is associated with increased production of II-1β in vivo. Baier et al. evaluated the role of II-1β 5IIC>T polymorphism in a population of very low birth weight infants. Compared to 14% with the C allele, one third of newborns with the T allele developed IVH. The II-1β −511T allele was strongly associated with the IVH grade 3 and 4 development [16]. Aden et al. analyzed II-1β −511C>T polymorphism and II-1β −31C polymorphism in 224 inborn preterm infants treated with AST and grade 3 and 4 IVH, finding a lack of association with IVH [17]. We investigated the role of II-1β +3953C>T polymorphism in the pathogenesis of IVH. A single-nucleotide polymorphism at position +3953 of the gene encoding IL-1β, which consists of the replacement of cytosine by thymine, leads to the emergence of a less frequent allele 2. This allele 2 is associated with increased production of IL-1β [18]. Our data demonstrates that the polymorphism II-1β +3953C>T is not a predictor of an increased risk of IVH.

Table 2 Demographic and clinical characteristic of enrolled infants

|                      | Group without IVH | Group with IVH grade 1-4 | p value | Group without IVH and with IVH grade 1 and 2 | Group with IVH grade 3-4 | p value |
|----------------------|-------------------|--------------------------|---------|-----------------------------------------------|--------------------------|---------|
| Gender               | N = 55( %)        | N = 45( % )              |         |                                               | N = 89( % )              |         |
| Male                 | 29 (52.73)        | 25 (55.56)               | 0.778a  |                                               | 47 (52.81)               | 7 (63.64)| 0.719b  |
| Female               | 26 (47.27)        | 20 (44.44)               |         |                                               | 42 (47.19)               | 4 (36.36)|         |
| Gestational age (weeks) |                  |                          |         |                                               |                          |         |
| 24 + 0–28 + 6        | 19 (34.55)        | 35 (77.78)               | 0.00002a|                                               | 44 (49.44)               | 10 (90.91)| 0.022b  |
| 29 + 0–32 + 0        | 36 (65.45)        | 10 (22.22)               |         |                                               | 45 (50.56)               | 1 (9.09) |         |
| Birth weight (g)     | <750              | 3 (5.45)                 | 0.0003a |                                               | 12 (13.48)               | 2 (18.18)| 0.057a  |
|                      | 750–1000          | 10 (18.18)               |         |                                               | 21 (23.60)               | 6 (54.55)|         |
|                      | >1000             | 42 (76.37)               |         |                                               | 56 (62.92)               | 3 (27.27)|         |
| Apgar score (median and range) |      |                          |         |                                               |                          |         |
| 1st minute           | 6 (1–10)          | 4 (1–10)                 | 0.0001c |                                               | 6 (1–10)                 | 3 (1–7)  | 0.054a  |
| 5th minute           | 8 (5–10)          | 7 (1–9)                  | 0.0005c |                                               | 7 (2–10)                 | 7 (1–8)  | 0.0099c |
| Mode of delivery     | Vaginal           | 17 (29.09)               | 0.039d  |                                               | 35 (39.30)               | 6 (54.55)| 0.520d  |
|                      | Cesarean section  | 38 (69.09)               |         |                                               | 21 (46.67)               | 54 (60.70)|         |
| Asphyxia (pH >7.0 or BE <-12) |       |                          |         |                                               |                          |         |
| Yes                  | 0 (0.00)          | 3 (6.98)                 | 0.084c  |                                               | 2 (2.30)                 | 1 (10.00)| 0.713b  |
| No                   | 54 (100.00)       | 40 (93.02)               |         |                                               | 85 (97.7)                | 9 (90.00)|         |
| Intrauterine infection |                  |                          |         |                                               |                          |         |
| Yes                  | 22 (40.00)        | 33 (73.33)               | 0.0009b |                                               | 46 (51.69)               | 9 (81.82)| 0.116b  |
| No                   | 33 (60.00)        | 12 (26.67)               |         |                                               | 43 (48.31)               | 2 (18.18)|         |
| Deaths               | 2 (3.63)          | 8 (17.77)                | 0.038b  |                                               | 5 (5.6)                  | 5 (45.45)| 0.0004b |

a Chi-square test
b Chi-square test with Yates’ correction
c Mann–Whitney U test
d Fisher–Freeman–Halton test
e Fisher’s exact test
Table 3  Genotype distribution of the five polymorphisms in infants without and with IVH or without/with IVH grades 1–2 and with IVH grades 3–4

| Gene symbol | Group without IVH | Group with IVH grades 1–4 | p value | OR | Group without IVH and IVH grade 1 and 2 | Group with IVH grades 3–4 | p value | OR |
|-------------|-------------------|---------------------------|---------|----|----------------------------------------|--------------------------|---------|----|
| IL-1β       |                   |                           |         |    |                                        |                          |         |    |
| +3955C>T    |                   |                           |         |    |                                        |                          |         |    |
| Genotype    | CC obs 32 (58.18) | 30 (66.67)                | –       |    | References 53 (59.55)                 | 9 (81.82)                | –       |    |
|             | CT obs 19 (34.55)| 12 (66.67)                | 0.509   | 0.674 (0.253–1.761) | 29 (32.58) | 2 (18.18) | 0.436 | 0.406 (0.040–2.173) |
|             | TT obs 4 (7.27)  | 3 (66.66)                 | 1.000   | 0.800 (0.108–5.178) | 7 (7.87)  | 0 (0.00)  | 0.716 | 0.000 (0.000–4.916) |
| Allele      | C 83 (75.45)      | 72 (80)                   | –       |    | References 135 (75.84)                | 20 (90.9)                | –       |    |
|             | T 27 (24.55)      | 18 (20)                   | 0.553   | 0.769 (0.367–1.586) | 43 (24.15) | 2 (9.1)   | 0.596 | 0.628 (0.148–2.024) |
| IL-1RN      |                   |                           |         |    |                                        |                          |         |    |
| 86 bp VNTR  | i/1 obs 28 (50.91)| 22 (48.89)                | –       |    | References 46 (51.69)                 | 4 (36.36)                | –       |    |
|             | i/2 obs 18 (32.73)| 15 (33.33)                | 1.000   | 1.061 (0.398–2.807) | 28 (31.46) | 5 (45.45) | 0.501 | 2.054 (0.401–11.17) |
|             | i/3 obs 7 (12.73)| 7 (15.51)                 | 0.920   | 1.273 (0.016–103.4) | 12 (13.48) | 2 (18.18) | 0.785 | 1.917 (0.154–15.15) |
| Allele      | 1 75 (68.18)      | 60 (66.66)                | –       |    | References 122 (68.53)                | 13 (59.1)                | –       |    |
|             | 2 33 (30)         | 29 (32.22)                | 0.879   | 1.098 (0.573–2.097) | 53 (29.77) | 9 (40.9)  | 0.437 | 1.594 (0.563–4.308) |
|             | 3 2 (1.81)        | 1 (1.11)                  | 1.000   | 0.625 (0.010–12.31) | 3 (1.68)  | 0         | 1.000 | 0.00 (0.000–24.38)  |
| IL-6        |                   |                           |         |    |                                        |                          |         |    |
| -174G>C     | GG obs 13 (23.64)| 8 (17.78)                 | –       |    | References 19 (21.35)                 | 2 (18.18)                | –       |    |
|             | GC obs 33 (60.00)| 28 (62.22)                | 0.718   | 1.379 (0.450–4.416) | 52 (58.43) | 9 (81.82) | 0.850 | 1.644 (0.298–16.9)  |
| Allele      | 1 26 (47.37)      | 17 (33.33)                | –       |    | References 26 (47.37)                 | 17 (33.33)               | –       |    |
|             | 2 33 (58.62)      | 29 (57.89)                | 0.879   | 1.098 (0.573–2.097) | 53 (29.77) | 9 (40.9)  | 0.437 | 1.594 (0.563–4.308) |
|             | 3 5 (8.93)        | 4 (7.89)                  | 1.000   | 0.625 (0.010–12.31) | 3 (1.68)  | 0         | 1.000 | 0.00 (0.000–24.38)  |
Table 3 (continued)

| Gene symbol | Group without IVH $N = 55$ (%) | Group with IVH grades 1–4 $N = 45$ (%) | $p$ value | OR | Group without IVH and IVH grade 1 and 2 $N = 89$ (%) | Group with IVH grades 3–4 $N = 11$ (%) | $p$ value | OR |
|-------------|---------------------------------|---------------------------------------|-----------|----|-----------------------------------------------------|---------------------------------------|-----------|----|
| exp         | 12.32                           | 12.60                                 |           |    | 21.75                                               | 1.84                                  |           |    |
| H-W         | 0.209                           | 0.081                                 | H–W       |    | 0.282                                               | 0.072                                 |           |    |
| Allele      |                                 |                                       |           |    |                                                     |                                       |           |    |
| G           | 59 (53.63)                      | 44 (48.88)                            |           |    | References                                           | 90 (50.56)                            |           |    |
| C           | 51 (46.36)                      | 46 (51.11)                            | 0.599     |    | 1.209 (0.667–2.195)                                  | 88 (49.43)                            |           |    |
| References  |                                 |                                       |           |    |                                                     |                                       |           |    |
| IL-6        | 1910 Childs Nerv Syst (2017) 33:1905–1916 |

- $596G>A$ (rs1800797)

**Genotype**

| Genotype | exp | GA obs | AA obs | exp | H–W | exp | GA obs | AA obs | exp | H–W |
|----------|-----|--------|--------|-----|-----|-----|--------|--------|-----|-----|
| GG obs   | 15  | 31     | 9      | 10  | 0.579|     | 0.579  | 0.579  |     |     |
| GG exp   | 0.27| 0.26  | 0.26   | 0.26| 0.388| 0.599| 0.388  | 0.599  | 0.26| 0.388|
| GA exp   | 0.23| 0.23  | 0.23   | 0.23| 0.13  | 0.531| 0.13   | 0.531  | 0.23| 0.13 |
| AA exp   | 0.15| 0.15  | 0.15   | 0.15| 0.15  | 0.531| 0.15   | 0.531  | 0.15| 0.15 |
| Allele   |     |        |        |     |      |     |        |        |     |     |
| G        | 15  | 31     | 9      | 10  | 0.579|     | 0.579  | 0.579  |     |     |
| A        | 49  | 44.55 | 45 (50)| 10  | 0.579|     | 0.579  | 0.579  |     |     |

- $308G>A$ (rs1800629)

**Genotype**

| Genotype | exp | GA obs | AA obs | exp | H–W | exp | GA obs | AA obs | exp | H–W |
|----------|-----|--------|--------|-----|-----|-----|--------|--------|-----|-----|
| GG obs   | 42  | 13     | 0      | 0   | 0.610| 0.704| 1.12   | 1.12   | 0   | 0.610|
| GG exp   | 0.27| 0.23  | 0.23   | 0.23| 0.23  | 0.23  | 0.23   | 0.23   | 0.23| 0.23 |
| GA exp   | 0.23| 0.23  | 0.23   | 0.23| 0.23  | 0.23  | 0.23   | 0.23   | 0.23| 0.23 |
| AA exp   | 0.15| 0.15  | 0.15   | 0.15| 0.15  | 0.15  | 0.15   | 0.15   | 0.15| 0.15 |
| Allele   |     |        |        |     |      |     |        |        |     |     |
| G        | 97  | 13     | 10     | 10  | 0.610| 0.704| 1.12   | 1.12   | 0   | 0.610|
| A        | 13  | 11.82 | 11.11  | 10  | 0.610| 0.704| 1.12   | 1.12   | 0   | 0.610|

Obs observed, Exp expected (genotype frequencies calculated from allele frequencies with the Hardy–Weinberg (H-W) equation)
| Gene symbol                  | Group without IVH | Group with IVH | p value | OR | Group without IVH and IVH grade 1 and 2 | Group with IVH | p value | OR |
|-----------------------------|-------------------|---------------|---------|----|----------------------------------------|---------------|---------|----|
| **IL-1β**                   |                   |               |         |    |                                        |               |         |    |
| +3953C>T (rs1143634)        |                   |               |         |    |                                        |               |         |    |
| Genotypes                   |                   |               |         |    |                                        |               |         |    |
| CC                          | 10 (52.63%)       | 25 (71.43%)   | 24.03   |    | References 27 (61.36%)                | 14 (31.82%)   | 2.27    |    |
| CT                          | 8 (42.11%)        | 8 (22.86%)    | 0.94    | 0.243 | 0.4                                      | 3 (6.82%)     | 0.27    |    |
| TT                          | 1 (5.26%)         | 2 (5.71%)     | 1.03    | 1.000 | 0.8                                      | 0 (0.00%)     | 0.10    |    |
| H-W                         | 0.933             | 0.513         |         |     |                                         | 0.823         | 0.940   |    |
| Allele                      |                   |               |         |    |                                        |               |         |    |
| C                           | 28 (73.68%)       | 58 (82.85%)   |         |    | References 68 (77.27%)                | 20 (22.72%)   | 2.03    |    |
| T                           | 10 (26.31%)       | 12 (17.15%)   |         | 0.377 | 0.579 (0.202–1.703)                    | 5 (14.29%)    | 4.24    |    |
| **IL-1RN 86 bp VNTR** (rs2234663) |                   |               |         |    |                                        |               |         |    |
| Genotypes                   |                   |               |         |    |                                        |               |         |    |
| I/1                         | 9 (47.37%)        | 18 (51.43%)   | 16.46   |    | References 24 (54.55%)                | 11 (25.00%)   | 18.52   |    |
| I/2                         | 4 (21.05%)        | 12 (34.29%)   | 15.09   | 0.827 | 1.5 (0.318–8.165)                      | 8 (18.18%)    | 4.24    |    |
| I/3                         | 0 (0.00%)         | 0 (0.00%)     |         |     | References 0 (0.00%)                  | 0 (0.00%)     | 0.10    |    |
| 2/2                         | 5 (26.32%)        | 5 (14.29%)    | 3.46    | 0.579 | 0.5 (0.089–2.852)                      | 8 (18.18%)    | 4.24    |    |
| 2/3                         | 1 (5.26%)         | 0 (0.00%)     | 0.714   |     | 0 (0.000–21.67)                       | 1 (2.27)      | 0.100   |    |
| H-W                         | 0.078             | 0.481         |         |     |                                         | 0.029         | 0.999   |    |
| Allele                      |                   |               |         |    |                                        |               |         |    |
| 1                            | 22 (57.89%)       | 48 (61.53%)   |         |    | References 59 (67.04%)                | 11 (55%)      |         |    |
| 2                            | 15 (39.47%)       | 22 (38.46%)   |         | 0.464 | 0.672 (0.272–1.683)                    | 28 (31.81%)   | 1.000   |    |
| 3                            | 1 (2.63%)         | 0             | 0.648   |     | 0 (0.000–18.69)                       | 1 (1.13%)     | 0.000   |    |
| **IL-6 –174G>C** (rs1800795) |                   |               |         |    |                                        |               |         |    |
| Genotypes                   |                   |               |         |    |                                        |               |         |    |
| GG                          | 6 (31.58%)        | 5 (14.29%)    | 9.26    |    | References 9 (20.45%)                 | 13.09         | 8 (0.00) |    |
| GC                          | 12 (63.16%)       | 26 (74.29%)   | 17.49   | 0.300 | 2.6 (0.529–12.93)                      | 21.82         | 8 (0.00) |    |

References:
- OR: Odds Ratio
- p value: Probability value
- H-W: Hardy-Weinberg Equilibrium
Table 4 (continued)

| Gene symbol | Group without IVH | Exp | Group with IVH | Exp | p value | OR   | Group without IVH | Exp | Group with IVH | Exp | p value | OR   |
|-------------|-------------------|-----|----------------|-----|---------|------|-------------------|-----|----------------|-----|---------|------|
|             | N=19 (%)          |     | N=35 (%)       |     |         |      | N=44 (%)          |     | N=10 (%)       |     |         |      |
| **CC**      |                   |     |                |     |         |      |                   |     |               |     |         |      |
|             | 1 (5.26)          | 2.58| 4 (11.43)      | 8.26| 0.462   | 4.8  | (0.294–275)       | 5 (11.36)| 9.09          | 0 (0.00)| 1.60     | 0.917| (0.000–12.15) |
|             | H-W               | 0.298| 0.016         |     |         |      |                   |     |               |     |         |      |
| Allele      |                   |     |                |     |         |      |                   |     |               |     |         |      |
|             | G                 | 24 (63.15%) | 36 (51.42%) |     | –       | References | 48 (54.54%) | 12 (60%) | –       | References |
|             | C                 | 14 (36.84%) | 34 (48.57%) | 0.333| 1.619   | (0.672–3.969)| 40 (45.45%) | 8 (40%)  | 0.808   | 0.764   | (0.229–2.401)|
| **IL-6 −596G>A** (rs1800797) |          |     |                |     |         |      |                   |     |               |     |         |      |
| Allele      |                   |     |                |     |         |      |                   |     |               |     |         |      |
| Genotypes  | GG                | 6 (31.58%) | 7.58          | 5 (14.29)| 9.78   | –       | References | 9 (20.45)| 13.64       | 2 (20.00)| 3.60   | –       | References |
|             | GA                | 12 (63.16%) | 8.84         | 27 (77.14)| 17.44 | 0.274   | 2.7       | (0.551–13.39)| 31 (70.45)| 21.72   | 8 (80.00)| 4.80   | 1.000  | (0.180–13.11) |
|             | AA                | 1 (5.26)  | 2.58          | 3 (8.57)| 7.78   | 0.677   | 3.6       | (0.191–219.9)| 4 (9.10) | 8.64    | 0 (0.00)| 1.60   | 1.000  | 0 (0.000–15.59) |
| H-W         |                   | 0.298   | 0.005         |     |         |      |                   |     |               |     |         |      |
| Allele      |                   |     |                |     |         |      |                   |     |               |     |         |      |
| Genotypes  | G                 | 24 (63.15%) | 37 (52.85%) |     | –       | References | 49 (55.68%) | 12 (60%) | –       | References |
|             | A                 | 14 (36.84%) | 33 (47.14%) | 0.408| 1.529   | (0.634–3.750)| 39 (44.31%) | 8 (40%)  | 0.838   | 0.779   | (0.234–2.448)|
| **TNF-α −308G>A** (rs1800629) |          |     |                |     |         |      |                   |     |               |     |         |      |
| Allele      |                   |     |                |     |         |      |                   |     |               |     |         |      |
| Genotypes  | GG                | 16 (84.21%) | 16.12        | 28 (80.00)| 28.35 | –       | References | 36 (81.82)| 36.36       | 8 (80.00)| 8.10   | –       | References |
|             | GA                | 3 (15.79)  | 2.76          | 7 (20.00)| 6.30  | 1.000   | 1.333     | (0.256–9.06)| 8 (18.18)| 7.27    | 2 (20.00)| 1.80   | 1.000  | (0.098–7.372) |
|             | AA                | 0 (0.00)   | 0.12          | 0 (0.00)| 0.35  | –       | –         | –         | 0 (0.00) | 0.36   | 0 (0.00)| 0.10   | –       | – |
| H-W         |                   | 0.933   | 0.806         |     |         |      |                   |     |               |     |         |      |
| Allele      |                   |     |                |     |         |      |                   |     |               |     |         |      |
| Genotypes  | G                 | 35 (92.1%) | 63 (90%)      |     | –       | References | 80 (90.9%) | 18 (90%) | –       | References |
|             | A                 | 3 (2.63%)  | 7 (10%)       | 1.000| 1.296   | (0.273–8.236)| 8 (9.1%)  | 2 (10%)  | 1.000   | 1.25    | (0.118–7.120)|

N observed, Exp expected (genotype frequencies calculated from allele frequencies with the Hardy–Weinberg (H-W) equation)
### Table 5  Genotype distribution of the polymorphisms in infected and non-infected infants with IVH grades 1–4 or with IVH grades 3–4

| Gene symbol | Group with IVH 1–4 infected (N = 33; %) | Group with IVH 1–4 non-infected (N = 14; %) | p value | OR | Group with IVH 3–4 infected (N = 9; %) | Group with IVH 3–4 non-infected (N = 2; %) | p value | OR |
|-------------|----------------------------------------|-----------------------------------------------|---------|----|----------------------------------------|-----------------------------------------------|---------|----|
| **IL-1β +3953C>T** *(rs1143634)* | | | | | | | | |
| Genotypes | | | | | | | | |
| CC         | 22 (66.67) | 8 (66.67) | 7.52 | References | 7 (77.78) | 7.11 | 2 (100.0) | 2 | References |
| CT         | 9 (27.27) | 3 (25.00) | 3.96 | 1.000 | 1.091 (0.196–7.820) | 2 (22.22) | 1.78 | 0 (0.00) | 0 | – |
| TT         | 2 (6.06) | 1 (8.33) | 0.52 | 1.000 | 0.727 (0.034–48.21) | 0 (0.00) | 0.11 | 0 (0.00) | 0 | – |
| H-W        | 0.731 | 0.703 | | H-W | 0.932 | | | |
| Allele C   | 53 (80.30) | 19 (79.17) | | References | 16 (88.89) | 6 (75.00) | | References |
| Allele T   | 13 (19.70) | 5 (20.83) | | References | 2 (11.11) | 2 (25.00) | | References |
| **IL-1RN 86 bp VNTR** *(rs2234663)* | | | | | | | | |
| Genotypes | | | | | | | | |
| 1/1        | 15 (45.45) | 7 (53.85) | 7.36 | References | 3 (33.33) | 2.78 | 1 (50.00) | 1.13 | References |
| 1/2        | 11 (33.33) | 4 (30.77) | 3.27 | 1.000 | 1.283 (0.246–7.497) | 4 (44.44) | 4.44 | 1 (50.00) | 0.75 | 1.000 | 1.333 (0.013–130.5) |
| 1/3        | 0 (0.00) | 1 (8.33) | 0.696 | 0.000 (0.000–20.80) | 0 (0.00) | 0 (0.00) | | References |
| 2/2        | 7 (21.21) | 0 (0.00) | 0.36 | – | References | 2 (22.22) | 1.78 | 0 (0.00) | 0.13 | – |
| IL-1RN (rs2234663) | | | | | | | | |
| 2/3        | 0 (0.00) | 0 (0.00) | | References | 0 (0.00) | 0 (0.00) | | References |
| Allele 1   | 41 (61.19) | 19 (82.61) | | References | 10 (55.56) | 3 (75.00) | | References |
| Allele 2   | 25 (38.81) | 4 (17.39) | 0.115 | References | 8 (44.44) | 1 (25.00) | 0.899 | 2.4 (0.150–141.5) |
| Allele 3   | 0 (0.00) | 0 (0.00) | | References | 0 (0.00) | 0 (0.00) | | References |
| **IL-6−174 G>C** *(rs1800795)* | | | | | | | | |
| Genotypes | | | | | | | | |
| GG         | 5 (15.15) | 3 (25.00) | 3.52 | – | References | 1 (11.11) | 2.78 | 1 (50.00) | 1.13 | – |
| GC         | 21 (63.64) | 7 (58.33) | 5.96 | 0.777 | 1.800 (0.218–12.22) | 8 (88.89) | 4.44 | 1 (50.00) | 0.75 | 0.691 | 8 (0.051–704) |
| CC         | 7 (21.21) | 2 (16.67) | 2.52 | 0.873 | 2.1 (0.162–32.92) | 0 (0.00) | 1.78 | 0 (0.00) | 0.13 | – |
| H-W        | 0.281 | 0.832 | | H-W | 0.056 | | 0.895 | |
| Allele G   | 31 (46.97) | 13 (54.17) | | References | 10 (55.56) | 3 (75.00) | | References |
| Allele C   | 35 (53.03) | 11 (45.83) | 0.715 | 1.334 (0.472–3.810) | 8 (44.44) | 1 (25.00) | 0.899 | 2.4 (0.150–141.5) |
| **IL-6−596 G>A** *(rs1800797)* | | | | | | | | |
| Genotypes | | | | | | | | |
| GG         | 5 (15.15) | 3 (25.00) | 4.08 | – | References | 1 (11.11) | 2.78 | 1 (50.00) | 1.13 | – |
| GA         | 21 (63.64) | 8 (66.67) | 5.83 | 0.888 | 1.575 (0.196–10.42) | 8 (88.89) | 4.44 | 1 (50.00) | 0.75 | 0.691 | 8 (0.051–704) |
| AA         | 7 (21.21) | 1 (8.33) | 2.08 | 0.569 | 4.2 (0.227–251.3) | 0 (0.00) | 1.78 | 0 (0.00) | 0.13 | – |
| H-W        | 0.281 | 0.437 | | H-W | 0.056 | | 0.895 | |
| Allele G   | 31 (46.97) | 14 (58.33) | | References | 10 (55.56) | 3 (75.00) | | References |
| Allele A   | 35 (53.03) | 10 (41.67) | 0.475 | 1.581 (0.557–4.583) | 8 (44.44) | 1 (25.00) | 0.899 | 2.4 (0.150–141.5) |
grade in preterm infants, which is a new finding in this group of patients.

IL-6 has a wide, bidirectional (pro-inflammatory and anti-inflammatory by acting against IL-1 and TNFα) spectrum of action including nervous system development [19]. The role of IL-6 in preterm brain injury, however, is unclear. No correlation was found between IL-6 concentration in cord blood and IVH development [20–22]. Comparatively, Heep et al. investigated postnatal levels of IL-6 in serum and found that IVH was present significantly more frequently in the group with IL-6 levels above 100 pg/ml [19]. The replacement of guanine by cytosine at position −174 of the IL-6 gene results in diminished production of IL-6 in homozygous CC individuals. Similarly, the replacement of guanine by adenosine at position −596 causes decreased IL-6 production by AA homozygotes [23]. Hording et al. reported that in preterm neonates, the CC genotype of IL-6 −174G>C polymorphism significantly increased the risk for IVH. These findings, however, have not been confirmed by Göpel et al., Baier et al., Ryckman et al., and Aden et al. [15–17, 24]. We did not find the association between genotypes of IL-6 −174G>C polymorphism and IVH. We were not able to confirm any association between genotypes of IL-6 −596G>A polymorphism either, which itself has not been previously reported.

TNFα is produced by activated macrophages and other cells. TNFα may participate in preterm brain injury in several ways, damaging the microcirculatory endothelium of the central nervous system and therefore increasing the risk of vessel rupture, stimulating the production of tissue factor and coagulation cascade activation, and stimulating the production of platelet-activating factor which can damage cell membranes [25]. The replacement of guanine by adenine at position −308 of the TNF gene promoter region causes the loss of the binding site for the AP-2 transcription factor [26]. The role of polymorphism −308 TNFα is ambiguous. Adcock et al. reported that allele A in the −308 TNFα promoter region is associated with IVH in preterm infants. Similar conclusions were reported in the studies of Heep et al., Ryckman et al., and Aden et al. [15, 17, 19]. Our analysis did not reveal the positive correlation between TNF −308G>A polymorphism with the prevalence of IVH.

The IL-1 receptor antagonist is a protein binding with receptors for IL-1 (IL-1 R1 and IL-1 R2). The VNTR polymorphism has been reported within intron 2 of the human IL-1 receptor antagonist gene, consisting of repeats of 86 bp sequence. The number of repeats is of functional significance as these repeats contain binding sites for transcription factors. The IL-1 RN1 allele corresponded to a 410 bp fragment (four copies of the −86 repeat), IL-1 RN0 to 154 bp, IL-1 RN2 to 240 bp, IL-1 RN3 to 500 bp, IL-1 RN4 to 325 bp, and IL-1 RN5 to 585 bp [27]. It is notable to mention that various alleles are associated with the production of this protein at different levels. IL-1 RN2 occurrence
leads to a prolonged and more intense pro-inflammatory response compared with those who do not carry this genotype [28]. In the present study, we examined the association of VNTR polymorphism of IL-1 RN with the IVH prevalence in preterm infants. To our knowledge, there has been no study investigating IL-1 RN gene polymorphism in preterm infants with IVH thus far. We have not found a correlation between the occurrence of the allele and prevalence of IVH.

The limitations of our study include the relatively small sample size, which could affect the demonstration of correlation between studied complications and polymorphisms. However, given the homogeneity of our population, it is unlikely that the observed associations are a statistical artifact resulting from a population substructure.

Conclusions

IVH is a significant problem for preterm infants. In addition to little progress in preventing IVH in preterm babies, substantial research that are focused on understanding the etiology, mechanism, and risk factors for IVH are imperative. In the era of personalized medicine, identification of genetic risk factors creates opportunities to generate preventative strategies. Further studies should be performed to confirm the role of genetic factors in etiology and pathogenesis of IVH.

Contributions

D.S. designed the research and wrote the manuscript. D.S., J.G., A.S-M., G.K., KD., and M.S. performed the research. D.S. collected and analyzed the data, and G.K. was responsible for the PCR procedure.

Compliance with ethical standards

Funding

This study was funded by Poznan University of Medical Sciences(grant number 502-14-02215338-09691).

Conflict of interest

All authors of this manuscript declare that they have no conflict of interest.

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study was approved by the Bioethics Committee of Poznan University of Medical Sciences(nr.66/14 and 799/).

Open Access

This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Bassan H (2009) Intracranial hemorrhage in the preterm infant: understanding it, preventing it. Clin Perinatol 36:737–762. doi: 10.1016/j.clp.2009.07.014
2. McCrea HJ, Ment LR (2008) The diagnosis, management, and postnatal prevention of intraventricular hemorrhage in the preterm neonate. Clin Perinatol 35:777–792
3. Ballabh P (2014) Pathogenesis and prevention of intraventricular hemorrhage. Clin Perinatol 41:47–67. doi: 10.1016/j.clp.2013.09.007
4. Sadowska-Krawcenko I, Janowska A, Kurylak A (2012) Healthcare-associated infections in a neonatal intensive care unit. Arch Med Sci 8:854–858. doi: 10.5114/ams.2012.31412
5. Ment LR, Adén U, Lin A et al (2014) Gene-environment interactions in severe intraventricular hemorrhage of preterm neonates. Pediatr Res 75:241–250. doi: 10.1038/pr.2013.195
6. Papile LA, Burstein J, Burstein R, Koffler H (1978) Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm. J Pediatr 92:529–534. doi: 10.1016/S0022-3476(78)80282-0
7. Park CK, Isayama T, McDonald SD (2016) Antenatal corticosteroid therapy before 24 weeks of gestation: a systematic review and meta-analysis. Obstet Gynecol 127:715–725
8. Mori R, Kusuda S, Fujimura M (2011) Antenatal corticosteroids promote survival of extremely preterm infants born at 22 to 23 weeks of gestation. J Pediatr 159:110–114.e1. doi: 10.1016/j.jpeds.2010.12.039
9. Roberts D, Dalziel S (2006) Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane database Syst Rev CD004454. doi: 10.1002/14651858.CD004454.pub2
10. Ment LR, Adén U, Bauer CR et al (2015) Genes and environment in neonatal intraventricular hemorrhage. Semin Perinatol 39:592–603. doi: 10.1053/j.semperi.2015.09.006
11. Briner A, Kalinka J (2010) IL-1β, IL-6 promoter, TNF-α promoter and IL-1RA gene polymorphisms and the risk of preterm delivery due to preterm premature rupture of membranes in a population of Polish women. Arch Med Sci 6:552–557. doi: 10.5114/ams.2010.14467
12. Adén U, Favrais G, Plaisant F et al (2010) Systemic inflammation sensitizes the neonatal brain to excitotoxicity through a pro-/anti-inflammatory imbalance: key role of TNFAlpha pathway and protection by etanercept. Brain Behav Immun 24:747–758. doi: 10.1016/j.bbi.2009.10.010
13. Sadowska GB, Threlkeld SW, Flangini A et al (2012) Ontogeny and the effects of in utero brain ischemia on interleukin-1β and interleukin-6 protein expression in ovine cerebral cortex and white matter. Int J Dev Neurosci 30:457–463. doi: 10.1016/j.ijdevneu.2012.06.001
14. Basu S, Agarwal P, Anupurba S et al (2015) Elevated plasma and cerebrospinal fluid interleukin-1 beta and tumor necrosis factor-alpha concentration and combined outcome of death or abnormal neuroimaging in preterm neonates with early-onset clinical sepsis. J Perinatol 35:855–861. doi: 10.1038/jp.2015.86
15. Ryckman KK, Dagle JM, Kelsey K et al (2011) Replication of genetic associations in the inflammation, complement, and coagulation pathways with intraventricular hemorrhage in LBW preterm neonates. Pediatr Res 70:90–95. doi: 10.1203/PDR.0b013e31821ceb63
16. Baier RJ (2006) Genetics of perinatal brain injury in the preterm infant. Front Biosci 11:1371–1387
17. Adén U, Lin A, Carlo W et al (2013) Candidate gene analysis: severe intraventricular hemorrhage in inborn preterm neonates. J Pediatr. doi:10.1016/j.jpeds.2013.06.025
18. S M, K J (2014) The role of chosen polymorphism of gens coding cytokines IL-1s, IL1ra, IL-6 and TNF alpha in the pathogenesis of the preterm delivery. Ginekol i Poloznictwo 33:9–23
19. Heep A, Behrendt D, Nitsch P et al (2003) Increased serum levels of interleukin 6 are associated with severe intraventricular haemorrhage in extremely premature infants. Arch Dis Child Fetal Neonatal Ed 88:F501–F504
20. Bhandari V, Buhimschi CS, Han CS et al (2011) Cord blood erythropoietin and interleukin-6 for prediction of intraventricular hemorrhage in the preterm neonate. J Matern Fetal Neonatal Med 24:673–679. doi:10.3109/14767058.2010.520048
21. Caldas JPS, Braghini CA, Mazzola TN et al (2015) Peri-intraventricular hemorrhage and oxidative and inflammatory stress markers in very-low birth weight newborns. J Pediatr 91:373–379. doi:10.1016/j.jpeds.2014.09.008
22. Sorokin Y, Romero R, Mele L et al (2014) Umbilical cord serum interleukin-6, C-reactive protein, and myeloperoxidase concentrations at birth and association with neonatal morbidities and long-term neurodevelopmental outcomes. Am J Perinatol 31:717–726. doi:10.1055/s-0033-1359723
23. Drews-Piasecka E, Seremak-Mrozikiewicz A, Barlik M et al (2014) The significance of TNF-α gene polymorphisms in preterm delivery. Ginekol Pol 85:428–434
24. Göpel W, Härtel C, Ahrens P et al (2006) Interleukin-6-174-genotype, sepsis and cerebral injury in very low birth weight infants. Genes Immun 7:65–68. doi:10.1038/sj.gene.636426
25. Szpecht D, Wiak K, Braszak A et al (2016) Role of selected cytokines in the etiopathogenesis of intraventricular hemorrhage in preterm newborns. Childs Nerv Syst. doi:10.1007/s00381-016-3217-9
26. Kroeger KM, Carville KS, Abraham LJ (1997) The −308 tumor necrosis factor-α promoter polymorphism effects transcription. Mol Immunol 34:391–399
27. Dinarello CA (2000) The role of the interleukin-1–receptor antagonist in blocking inflammation mediated by interleukin-1. N Engl J Med 343:732–734
28. Witkin SS, Gerber S, Ledger WJ (2002) Influence of interleukin-1 receptor antagonist gene polymorphism on disease. Clin Infect Dis 34:204–209. doi:10.1086/338261